William Blair Reiterates a Buy on Terns Pharmaceuticals (TERN)

​The standing follows the company’s fiscal third-quarter results announced connected November 10. The institution reported affirmative momentum for its CARDINAL programme for its TERN-701, which is successful Phase 1 proceedings for treating chronic myeloid leukemia. Earlier successful November, Terns Pharmaceuticals, Inc. (NASDAQ:TERN) released an abstract with updated information from the ongoing Phase 1 CARDINAL trial, which showed encouraging results suggesting TERN-701 tin go a best-in-disease treatment.

​Andy Hsieh of William Blair noted the archetypal results from the survey suggest that TERN-701 has the imaginable to interaction the chronic myeloid leukemia attraction market. Hsieh believes the cause tin situation the existent marketplace leaders, including Scemblix, for some treatment-naive and relapsed populations. Moreover, the expert besides likes the company’s fiscal presumption with $295 cardinal successful cash, expected to money operations into 2028.

​Terns Pharmaceuticals, Inc. (NASDAQ:TERN) is simply a clinical-stage biopharmaceutical institution processing small-molecule merchandise candidates to dainty superior diseases, including crab and obesity.

While we admit the imaginable of TERN arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double successful 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This nonfiction is primitively published astatine Insider Monkey.